As shown above, in hematologic malignancies the mTOR activation, working in opposition with AMPK but in concert with other oncogenes such as Bcr-Abl, or metabolic modulators like HIF1α, contributes to confer the glycolytic phenotype by directly and indirectly regulating key glycolytic enzyme activity (Figure 2). Here, MTOR is linked to hematologic disorder.